Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 2025 年 3 月 27 日、6 月 30 日，西藏卫信康医药股份有限公司（以下简称"公 司"）及全资子公司西藏中卫诚康药业有限公司收到 2024 年企业发展金合计 3,434.37 万元，该笔政府补助与收益相关，占公司 2024 年度经审计归属于上市 公司股东净利润的 13.95%。 二、补助的类型及其对公司的影响 证券代码：603676 证券简称：卫信康 公告编号：2025-043 西藏卫信康医药股份有限公司 2025 年 7 月 1 日 公司将按照《企业会计准则第 16 号——政府补助》相关规定，将上述与收 益相关的政府补助 3,434.37 万元列入其他收益。上述政府补助的取得，将对公 司 2025 年度的净利润产生一定影响。具体的会计处理及其对公司相关财务数据 的影响将以会计师事务所年度审计确认后的结果为准。敬请广大投资者注意投资 风险。 西藏卫信康医药股份有限公司董事会 特此公告。 ...

证券代码：603676 证券简称：卫信康 公告编号：2025-042 西藏卫信康医药股份有限公司 关于公司合作产品通过仿制药质量和疗效一致性评价的公告 申请类型：补充申请 受理号：CYHB2350909 药品注册标准编号：YBH15202025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，西藏卫信康医药股份有限公司（以下简称"公司"）合作生产方山西普德药 业有限公司（以下简称"普德药业"）收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的注射用多种维生素（12）《药品补充申请批准通知书》，该药品通过仿 制药质量和疗效一致性评价。注射用多种维生素（12）系由公司自主研发、普德药业负 责药品注册、生产，为公司核心产品。现就相关事项公告如下： 一、药物基本情况 药物名称：注射用多种维生素(12) 剂型：注射剂 注册分类：化学药品 规格：5ml/支 原药品批准文号：国药准字 H20093720 上市许可持有人：山西普德药业有限公司 药品生产企业：山西普德药业有限公司 审批结论：根据《中华人民共和国药品管理法》、《国 ...

Group 1 - The core point of the news is that Weixin Kang has experienced a decline in stock price, with a cumulative drop of -10.07% over seven consecutive trading days [1] - Weixin Kang Pharmaceutical Co., Ltd. was founded in 2002 and officially established in 2006, with its shares listed on the Shanghai Stock Exchange in 2017 under the stock code 603676.SH [1] - The financial report indicates that the fund under China Merchants Fund, specifically the China Merchants Quantitative Selected Stock A, has increased its holdings in Weixin Kang and has achieved a year-to-date return of 9.35%, ranking 224 out of 997 in its category [1] Group 2 - The performance data shows that the fund has had a near-term decline of -1.13% over the past week, but a positive return of 9.31% year-to-date, outperforming the average of its peers [2] - The fund manager, Wang Ping, has extensive experience in risk management and quantitative investment, having joined China Merchants Fund in 2006 and currently managing multiple funds [4][5] - The total assets under management for the funds managed by Wang Ping amount to 170.64 billion, with a cumulative return of 191.33% [5]

Core Viewpoint - The legal opinion letter issued by Guangdong Xinda Law Firm confirms the compliance of Tibet Weixin Pharmaceutical Co., Ltd.'s differentiated equity distribution plan for the 2024 profit distribution, ensuring that repurchased shares do not participate in the profit distribution [2][12]. Group 1: Differentiated Equity Distribution Plan - The company plans to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares to all shareholders, with a total share capital of 435,161,500 shares after deducting repurchased shares [8][9]. - As of the announcement date, the company has repurchased 2,826,700 shares, which will not participate in the profit distribution [9][12]. - The company will maintain the per-share distribution ratio even if the total share capital changes due to repurchases or other factors, with adjustments announced separately [8]. Group 2: Reasons for Differentiated Equity Distribution - The differentiated equity distribution is part of a broader strategy to enhance shareholder value and investor confidence, with a planned repurchase fund of no less than 15 million yuan and no more than 30 million yuan [8][9]. - The repurchase price is capped at 12.12 yuan per share, with a maximum duration of 12 months from the board's approval [8]. Group 3: Legal Compliance and Calculations - The legal opinion confirms that the differentiated equity distribution complies with relevant laws and regulations, including the Company Law and Securities Law [12][13]. - The calculation for the ex-rights and ex-dividend reference price is based on the formula that considers the cash dividend and the change in circulating shares, with the impact on the reference price being minimal [12][13].

证券代码：603676 证券简称：卫信康 公告编号：2025-041 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.18元（含税） ? 相关日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。公司回购专用证券账 户所持有的公司股份不参与本次利润分配。 （1）本次差异化分红方案 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/10 | － | 2025/6/11 | 2025/6/11 | | ? 差异化分红： 是 一、通过分配方案的股东大会届次和日期 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购专用证券账户中的 股 ...

证券代码：603676 证券简称：卫信康 公告编号：2025-041 西藏卫信康医药股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.18元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/10 | － | 2025/6/11 | 2025/6/11 | 差异化分红： 是 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。公司回购专用证券账 户所持有的公司股份不参与本次利润分配。 3. 差异化分红方案： （1） ...

西藏卫信康医药股份有限公司 差异化权益分派事项的法律意见书 关于 中国 深圳 福田区益田路6001号太平金融大厦11、12层 邮政编码：518038 11-12/F, Taiping Finance Tower, Yitian Road No.6001, Futian District, Shenzhen 518038 电话(Tel)：(0755)88265288 传真(Fax)：(0755)88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网站（Website）：sundiallawfirm.com 法律意见书 广东信达律师事务所 关于西藏卫信康医药股份有限公司 差异化权益分派事项的法律意见书 信达专字[2025]第 009 号 致：西藏卫信康医药股份有限公司 广东信达律师事务所（以下简称"信达"）接受贵公司的委托，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司股份回购规则》《上 海证券交易所交易规则》《上海证券交易所上市公司自律监管指引第 7 号——回 购股份》等有关法律、法规及规范性文件的规定，就贵公司 2024 年度利润分配 涉及的差异化权益 ...

Core Viewpoint - The legal opinion issued by Guangdong Xinda (Beijing) Law Firm confirms the legality and validity of the convening and proceedings of the 2024 annual general meeting of shareholders for Tibet Weixin Pharmaceutical Co., Ltd. [2][3][7] Group 1: Meeting Convening and Procedures - The board of directors announced the 2024 annual general meeting on April 26, 2025, detailing the convenor, time, method, and agenda [3][5] - The meeting was held on May 16, 2025, with both on-site and remote video participation options available for shareholders [5][6] - The meeting followed the legal requirements set forth in the Company Law and the rules for shareholder meetings [6][7] Group 2: Attendance and Voting - A total of 98 participants attended the meeting, representing 297,747,235 shares, which is 68.87% of the total voting shares [6][7] - The qualifications of the shareholders and their proxies were verified and deemed valid for participation [6][7] Group 3: Voting Procedures and Results - All proposed resolutions were effectively voted on, with special resolutions requiring a two-thirds majority [7][9] - The voting results were announced immediately, confirming that all resolutions passed with significant majorities [7][9] - Detailed voting results are included in the attached summary table [8][9]

证券代码：603676 证券简称：卫信康 公告编号：2025-040 西藏卫信康医药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 05 月 16 日 (二) 股东大会召开的地点：北京市昌平区科技园区东区产业基地何营路 8 号院 5 号楼 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事7人，出席7人； 2、公司在任监事3人，出席3人； 3、公司董事会秘书出席了本次会议，其他高管列席了本次会议。 二、 议案审议情况 (一) 非累积投票议案 1、议案名称：公司 2024 年度董事会工作报告 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情 况： | 1、出席会议的股东和代理人人数 | 98 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 297,747,235 | | 3、出席会议的股东所持有表决权股份 ...